The mechanisms of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC are diverse, including genomic mechanisms such as point mutations, amplifications, and oncogenic fusions [6,7]. Here, EGFR is linked to non-small cell lung carcinoma.